Vanangamudi M - Search Results

1

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).

Vanangamudi M, Palaniappan S, Kathiravan MK, Namasivayam V. Vanangamudi M, et al. Viruses. 2023 Sep 25;15(10):1992. doi: 10.3390/v15101992. Viruses. 2023. PMID: 37896769 Free PMC article. Review.

2

HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).

Vanangamudi M, Poongavanam V, Namasivayam V. Vanangamudi M, et al. Curr Med Chem. 2017 Nov 17;24(34):3774-3812. doi: 10.2174/0929867324666170705122851. Curr Med Chem. 2017. PMID: 28685686 Review.

3

The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Namasivayam V, Vanangamudi M, Kramer VG, Kurup S, Zhan P, Liu X, Kongsted J, Byrareddy SN. Namasivayam V, et al. Among authors: vanangamudi m. J Med Chem. 2019 May 23;62(10):4851-4883. doi: 10.1021/acs.jmedchem.8b00843. Epub 2018 Dec 27. J Med Chem. 2019. PMID: 30516990 Free PMC article.

4

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens.

Vanangamudi M, Kurup S, Namasivayam V. Vanangamudi M, et al. Curr Opin Pharmacol. 2020 Oct;54:179-187. doi: 10.1016/j.coph.2020.10.009. Epub 2020 Nov 14. Curr Opin Pharmacol. 2020. PMID: 33202360 Review.

5

Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.

Vanangamudi M, Nair PC, Engels SEM, Palaniappan S, Namasivayam V. Vanangamudi M, et al. Adv Exp Med Biol. 2021;1322:63-95. doi: 10.1007/978-981-16-0267-2_3. Adv Exp Med Biol. 2021. PMID: 34258737

6

Repurposing drugs targeting epidemic viruses.

Namasivayam V, Palaniappan S, Vanangamudi M. Namasivayam V, et al. Among authors: vanangamudi m. Drug Discov Today. 2022 Jul;27(7):1874-1894. doi: 10.1016/j.drudis.2022.04.008. Epub 2022 Apr 12. Drug Discov Today. 2022. PMID: 35427764 Review.

7

Hydroxytriazenes incorporating sulphonamide derivatives: evaluation of antidiabetic, antioxidant, anti-inflammatory activities, and computational study.

Chauhan LK, Chopra J, Vanangamudi M, Tripathi IP, Bhargava A, Goswami AK, Baroliya PK. Chauhan LK, et al. Among authors: vanangamudi m. Mol Divers. 2023 Feb;27(1):223-237. doi: 10.1007/s11030-022-10420-w. Epub 2022 Apr 12. Mol Divers. 2023. PMID: 35414151

8

Novel naphthyl based 1,2,4-trioxanes: Synthesis and in vivo efficacy in the Plasmodium yoelii nigeriensis in Swiss mice.

Karnatak M, Hassam M, Vanangamudi M, Sharma S, Kumar Yadav D, Singh C, Puri SK, Rawat V, Prakash Verma V. Karnatak M, et al. Among authors: vanangamudi m. Bioorg Med Chem Lett. 2021 Nov 1;51:128372. doi: 10.1016/j.bmcl.2021.128372. Epub 2021 Sep 20. Bioorg Med Chem Lett. 2021. PMID: 34547418

9

Hepatoprotective effect of flavonoid rich fraction of Sesbania grandiflora: Results of In vivo, in vitro, and molecular docking studies.

Kuttiappan A, Chenchula S, Vanangamudi M, Bhatt S, Chikatipalli R, Shaila Bhanu P, Bandaru N. Kuttiappan A, et al. Among authors: vanangamudi m. J Ayurveda Integr Med. 2024 Sep-Oct;15(5):101036. doi: 10.1016/j.jaim.2024.101036. Epub 2024 Sep 6. J Ayurveda Integr Med. 2024. PMID: 39243548 Free PMC article.

10

Synthesis of sulpha drug based hydroxytriazene derivatives: Anti-diabetic, antioxidant, anti-inflammatory activity and their molecular docking studies.

Sharma P, Dayma V, Dwivedi A, Baroliya PK, Tripathi IP, Vanangamudi M, Chauhan RS, Goswami AK. Sharma P, et al. Among authors: vanangamudi m. Bioorg Chem. 2020 Mar;96:103642. doi: 10.1016/j.bioorg.2020.103642. Epub 2020 Jan 31. Bioorg Chem. 2020. PMID: 32062065

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters